FORGOT YOUR DETAILS?

The drug pricing controversy in the US reaches full boil

exclusive breakfast panel

Monday, jan 7th 2019
7:00 - 8:30a

grand hyatt union square
345 stockton street, san francisco

Business as usual is over. What comes next?

New proposals on managing drug prices are coming from left, right and center — and by no means are they always originating at the expected sources. At a time when the industry is squarely confronted with a sea change on the management of drug portfolios, access to medicines and the annual price hikes that drive profitability, we now have a president who has advocated importing overseas drug prices as a way to control the Medicare spend, and possibly much, much more. We’ll assemble the industry’s top execs to discuss how they’re bracing for the brave new world ahead, and how that will influence the global industry when it comes to innovation and development.

panelists

Christi Shaw

President
Lilly Bio-Medicines

Kathleen Tregoning

EVP, External Affairs
Sanofi

Peter B. Bach

Director, Center for Health Policy & Outcomes - MSKCC

Jeff Marrazzo

CEO
Spark Therapeutics

Stephen Ubl

President & CEO
PhRMA

John Carroll

Founder & Editor
Endpoints News

exclusive sponsor

Christi Shaw

Senior Vice President, Eli Lilly & President, Lilly Bio-Medicines

Christi Shaw is a senior vice president of Eli Lilly and Company and president of Lilly Bio-Medicines.

Before she rejoined Lilly in April 2017, she had most recently served as U.S. country head and president of Novartis Corporation.

Christi serves as a board member of the Biotechnology Industry Organization (BIO) and an advisor to the Healthcare Businesswomen’s Association. In 2018, Christi was honored with the Health Industry Visionary Award by the Society for Women’s Health Research. In May 2016, she was presented with Eye for Pharma’s prestigious Lifetime Achievement Award for her industry thought-leadership and dedication to the needs of patients. Also in 2016, PharmaVOICE named Shaw to its 100 Most Inspiring People list, and Diversity Journal included her on its roster of Women Worth Watching. Christi has spoken at leading industry conferences on the future of health care, driving innovation to support better patient outcomes and encouraging a diverse and inclusive culture. In addition, her perspectives have been featured in Working Mother and Life Science Leader magazines.

Christi worked at Lilly from 1989 to 2002 in sales and marketing roles, and she later held a series of increasingly responsible roles in the Janssen and Ethicon subsidiaries of Johnson & Johnson.

She earned a Bachelor of Business Administration from Iowa State University and an MBA from the University of Wisconsin. 

In 2017, Shaw founded the More Moments More Memories Foundation to assist people with cancer and their caregiver.

Kathleen Tregoning

Executive Vice President, External Affairs - Sanofi

A U.S. citizen, Ms. Tregoning has a bachelor of arts in international relations from Stanford and a master of arts from Harvard University, John F. Kennedy School of Government.

She has more than 20 years of professional experience in policy, advocacy, stakeholder outreach and external engagement. She began her career in 1993 with Andersen Consulting in San Francisco and then later served as Assistant Deputy Mayor, Office of the Mayor for the City of Los Angeles. In 2001, Ms. Tregoning moved to Washington, D.C. where she served in various healthcare policy positions in the United States Senate and United States House of Representatives, including a tenure with the House Ways & Means Committee. She joined Biogen in 2006 as Vice President, Public Policy & Government Affairs and in 2015 was appointed Senior Vice President, Corporate Affairs.

She was appointed to her present position in February 2017.

Jeff Marrazzo

Chief Executive Officer
Spark Therapeutics

Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark’s board of directors.

Under Jeff’s leadership, Spark has received FDA approval for and launched the first gene therapy for a genetic disease in the United States, and has established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In the five years since founding Spark, Jeff has secured more than $1 billion in capital and built an organization of more than 325 colleagues. For two years running, Spark has been named to the top 10 of MIT Technology Review’s “50 Smartest Companies”. It’s also been recognized as one of 2018’s most innovative companies in Biotech by Fast Company.

During a career that has spanned the public and private sectors, Jeff has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark, he helped build the first genetic testing benefit management and pharmacogenomics medicines company up to and through the acquisition of a majority of the company's shares by CVS Caremark. Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare.

Jeff currently serves as a board member of the Biotechnology Innovation Organization (BIO). Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.

Peter B. Bach

Director, Center for Health Policy & Outcomes - MSKCC

Peter B. Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients.

Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year.

In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer.

Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006.

Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes.

Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008.

Stephen Ubl

President & CEO
PhRMA

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The biopharmaceutical sector directly employs more than 854,000 Americans, and invests more than $70 billion in research and development every year -- more than any other industry in America.

Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl,” the New York Times’ Robert Pear wrote in February 2016. “He is more conversant with the intricacies of health policy, and more adept at the politics.”

As president and CEO of medical technology association AdvaMed, Ubl helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).

He is routinely recognized as one of Washington’s most effective advocates, and, in 2018, was named for the third year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare” and a top health influencer by Medical Marketing & Media and PR Week magazines.

Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals. He began his Washington career on Capitol Hill.

John Carroll

Founder & Editor
Endpoints News

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism.

A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his previous daily industry coverage at FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard.

Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Businessand early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.

© 2018 Endpoints Company

TOP